Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Concordia Healthcare Corp. T.CXR.R

TSX:CXR.R - Post Discussion

Concordia Healthcare Corp. > Took time out to dissect the Presentation - CIBC is Wrong -
View:
Post by ryehigh2014 on Oct 16, 2016 4:08pm

Took time out to dissect the Presentation - CIBC is Wrong -

Below I`ve pasted a Proforma I/S for Q3 - Q4 (i know its early). Most assumptions are relative to Revenue. I factor in a 1.21 GBPUSD rate and a 1.10 GBPUSD for Q3 and Q4/2016 respectively. Furthermore project negative 10% of revenue growth for Q3/Q4. See below for I/S snapshot.

 
 
Income Statement     Historical  
  Units QY03 QY06 QY09 QY12 TOTAL
Revenue  $ Thousands   $            228,535  $          231,712  $        222,891  $     214,478  $        897,616
Concordia International  $ Thousands   $            139,913  $          151,477  $        145,418  $     139,601  $        576,409
Concordia Orphan Drugs  $ Thousands   $                 2,674  $               2,744  $              2,744  $           2,744  $           10,906
Concordia North America  $ Thousands   $               85,948  $             77,491  $           74,729  $        72,133  $        310,301
Concordia Legacy Drugs  $ Thousands   $               29,197  $             31,461  $           31,461  $        31,461  $        123,581
Covis  $ Thousands   $               56,751  $             46,030  $           43,268  $        40,672  $        186,720
             
 EBITDA     $            106,943  $        (441,212)  $        112,438  $     106,615  $      (115,216)
 EBITDA + Impairment     $            106,943  $          125,864  $        112,438  $     106,615  $        451,860
Comment by ryehigh2014 on Oct 16, 2016 4:11pm
Cash Flow Statement     Historical       QY03 QY06 QY09 QY12 Total Cash flow from Operations             Net Income (loss) from continuing Operations  $  ...more  
Comment by ryehigh2014 on Oct 16, 2016 4:19pm
Apologize. I dont think anyone can see the post properly. Anywasy to summarize.  Cash on hand expected after Q4 - 203MM. I expect 2 NI losses going forward. NOL tax carry forwards will be HUGE (and beneficial). I expect acquisitions to the tune of ~30MM a year. I also expect EXTREMELY negative growth rates of -10% a quarter to start (which is very unlikely) (-6% for North American Business ...more  
Comment by Marky1 on Oct 16, 2016 4:51pm
Thank you for all the work that you've done for all of us rye high !! Appreciate it...
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities